Advertisement
Advertisement
IMVT
Immunovant, Inc. Common Stock
35.71
USDSponsored
+0.56
+1.59%
Nov 10, 15:59 UTC -5
Closed
After-Market
35.31
-0.40
-1.12%
Immunovant, Inc. Common Stock (IMVT) Earnings
IMVT Earnings Reports
Positive Surprise Ratio
IMVT beat 12 of 27 last estimates.
44%
Next Report
Date of Next Report
Feb 04, 2027
Estimate for Q3 27 (Revenue/ EPS)
--
/-$0.74
Implied change from Q2 27 (Revenue/ EPS)
--
/+57.45%
Implied change from Q3 26 (Revenue/ EPS)
--
/+21.31%
Immunovant, Inc. Common Stock earnings per share and revenue
On Nov 09, 2026, IMVT reported earnings of -0.47 USD per share (EPS) for Q2 27, beating the estimate of -0.74 USD, resulting in a 37.07% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +15.13% price change (close before vs. close after earnings).
Looking ahead to Q3 27, -- analysts forecast an EPS of -0.74 USD, with revenue projected to reach -- USD, implying an increase of 57.45% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Immunovant, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2027?
For Q2 2027, Immunovant, Inc. Common Stock reported EPS of -$0.47, beating estimates by 37.07%, and revenue of $0.00, 0% as expectations.
How did the market react to Immunovant, Inc. Common Stock's Q2 2027 earnings?
The stock price moved up 15.13%, changed from $30.53 before the earnings release to $35.15 the day after.
When is Immunovant, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 04, 2027.
What are the forecasts for Immunovant, Inc. Common Stock's next earnings report?
Based on --
analysts, Immunovant, Inc. Common Stock is expected to report EPS of -$0.74 and revenue of -- for Q3 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.